WO2010080414A3 - Substituted fno (2-[furan-2-yl] naphthalen-1-ol) derivatives as anti-cancer agents - Google Patents

Substituted fno (2-[furan-2-yl] naphthalen-1-ol) derivatives as anti-cancer agents Download PDF

Info

Publication number
WO2010080414A3
WO2010080414A3 PCT/US2009/068163 US2009068163W WO2010080414A3 WO 2010080414 A3 WO2010080414 A3 WO 2010080414A3 US 2009068163 W US2009068163 W US 2009068163W WO 2010080414 A3 WO2010080414 A3 WO 2010080414A3
Authority
WO
WIPO (PCT)
Prior art keywords
fno
naphthalen
furan
derivatives
substituted
Prior art date
Application number
PCT/US2009/068163
Other languages
French (fr)
Other versions
WO2010080414A2 (en
Inventor
Kuo-Hsiung Lee
Yizhou Dong
Qian Shi
Kenneth F. Bastow
Original Assignee
The University Of North Carolina At Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of North Carolina At Chapel Hill filed Critical The University Of North Carolina At Chapel Hill
Publication of WO2010080414A2 publication Critical patent/WO2010080414A2/en
Publication of WO2010080414A3 publication Critical patent/WO2010080414A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds of Formulas I are described, along with methods of using such compounds for the treatment of cancer and pharmaceutical formulations thereof.
PCT/US2009/068163 2008-12-19 2009-12-16 Substituted fno (2-[furan-2-yl] naphthalen-1-ol) derivatives as anti-cancer agents WO2010080414A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13920808P 2008-12-19 2008-12-19
US61/139,208 2008-12-19

Publications (2)

Publication Number Publication Date
WO2010080414A2 WO2010080414A2 (en) 2010-07-15
WO2010080414A3 true WO2010080414A3 (en) 2010-11-04

Family

ID=42317059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/068163 WO2010080414A2 (en) 2008-12-19 2009-12-16 Substituted fno (2-[furan-2-yl] naphthalen-1-ol) derivatives as anti-cancer agents

Country Status (1)

Country Link
WO (1) WO2010080414A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2821412A1 (en) 2010-12-16 2012-06-21 N30 Pharmaceuticals, Inc. Novel substituted bicyclic aromatic compounds as s-nitrosoglutathione reductase inhibitors
CN103588739A (en) * 2011-03-25 2014-02-19 上海长恒生物医药科技有限公司 Nitrofurans compounds, preparation method and application of nitrofurans compounds
US20160022625A1 (en) * 2013-03-06 2016-01-28 Jie Zheng Tashinones and their derivatives: novel excellent drugs for alzheimer disease
CN103992332B (en) * 2014-06-06 2016-01-13 广西师范大学 Prepare the method for furans [3,2-C] coumarin compound
CN106243071A (en) * 2016-07-15 2016-12-21 中国人民解放军第四军医大学 New derivatives of tanshinone IIA and its preparation method and application
CN112573999B (en) * 2019-09-29 2022-09-02 中国海洋大学 Preparation method of 3-chlorogentitol

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250751A1 (en) * 2004-03-10 2005-11-10 Kuo-Hsiung Lee Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents
US20070207989A1 (en) * 2006-03-03 2007-09-06 Savipu Pharmaceuticals Diterpene derivatives for the treatment of cardiovascular, cancer and inflammatory diseases
US20080187608A1 (en) * 2007-02-05 2008-08-07 Savipu Pharmaceuticals Enriched fractions from clary sage for the treatment of cancer, cardiovascular and inflammatory diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250751A1 (en) * 2004-03-10 2005-11-10 Kuo-Hsiung Lee Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents
US20070207989A1 (en) * 2006-03-03 2007-09-06 Savipu Pharmaceuticals Diterpene derivatives for the treatment of cardiovascular, cancer and inflammatory diseases
US20080187608A1 (en) * 2007-02-05 2008-08-07 Savipu Pharmaceuticals Enriched fractions from clary sage for the treatment of cancer, cardiovascular and inflammatory diseases

Also Published As

Publication number Publication date
WO2010080414A2 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
WO2009111653A3 (en) Antiviral therapeutic agents
WO2009156462A3 (en) Organic compounds
WO2007135527A3 (en) Benzimidazolyl compounds
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
BRPI0915084B8 (en) compound, and, pharmaceutical composition
EP1841761A4 (en) Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
WO2008013838A3 (en) Pyridizinone derivatives
WO2009007751A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2009026166A3 (en) Antiinfective flavonol compounds and methods of use thereof
EA201001196A1 (en) 4-PYRIDINONE COMPOUNDS AND THEIR APPLICATION FOR CANCER TREATMENT
WO2009046842A3 (en) Thiazol derivatives for treating cancer
WO2007075825A3 (en) Lipophilic anticancer drug compounds
WO2009105969A8 (en) Epothilone analogues, their pharmaceutical compositions, their use and their preparations
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2010067078A8 (en) 3,6-disubstituted xanthylium salts
WO2007081694A3 (en) Derivatives of sulindac, use thereof and preparation thereof
WO2010080414A3 (en) Substituted fno (2-[furan-2-yl] naphthalen-1-ol) derivatives as anti-cancer agents
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
BRPI0922870A2 (en) use of at least one compound of formula i, the ohod compound or pharmaceutically acceptable derivatives thereof, the na-ohod compound, the pharmaceutical and / or nutraceutical composition and the cosmetic method
BRPI0720323A2 (en) compound, method of treatment, pharmaceutical composition and use of the compound
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors
WO2010089327A3 (en) Indole derivatives as anticancer agents
WO2010121675A3 (en) Thiazolyl-benzimidazoles
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09837884

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09837884

Country of ref document: EP

Kind code of ref document: A2